대화제약

067080KOSDAQ의약품 제조업

45.4 / 100

Reference Date: 2026-07-24

Financial Score9.5 / 40

News Sentiment16.9 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: PER raises overvaluation concerns, PBR raises overvaluation concerns. Declined 5.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Dae Hwa Pharmaceutical primarily engages in the manufacturing and sales of pharmaceuticals, medical devices, and raw materials, supplying a wide range of products such as antibiotics and pain relievers both domestically and internationally. The company has expanded its overseas markets through partnerships with German and Chinese firms and focuses on R&D investment for new drug development.

Number of Employees

369people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

99.36Industry Average 11.230.0Point

8.8x industry avg (risky)

PBR

2.20Industry Average 0.810.0Point

2.7x industry avg (risky)

ROE

3.00Industry Average 4.012.5Point

Below industry avg

Debt Ratio

12.94Industry Average 12.432.0Point

Higher than industry avg (caution)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲94.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.1% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Neutral
“李대통령 발언에 미프진 빗장 풀리나”…현대약품 상한가·지분 보...
제약 업종 전반적인 하락세로 인해 대화제약의 직접적인 영향은 제한적임.
Positive
[특징주] 현대약품, 李 대통령 ‘미프진’ 언급에 이틀째 급등…15%↑
이재명 대통령의 미프진 관련 발언으로 현대약품 주가가 이틀 연속 급등했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 9,340Won52-week high 23,30052-week low 8,550

1-month return2.0Point

1m -5.08% (slight drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-22
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-02